Signal Genetics, Inc. (NASDAQ:SGNL) traded with the volume of 1.24 Million in the previous trading session. The Stock opened its session at $0 and closed at $17.48 by showing increase of 264.93 percent. Signal Genetics, Inc. has 1 year price target of $33.75. The stock gained a consensus recommendation of 1 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company reported its last quarter on Jun 16.
On Jun 16 Signal Genetics, Inc. (NASDAQ:SGNL) reported its EPS in the last quarter as $-3.45/Share lagging the analyst estimate of $-2.78/Share by the difference of $-0.67. This showed the surprise of -24.1% in the last quarter earnings.
There is no forecast data available. (CNN MONEY)
Signal Genetics, Inc. (NASDAQ:SGNL) topped its 52-week high price of $17.5 on Jan 10, 2017 and 52-Week Low Price of $0.12 on Nov 4, 2016. The Stock currently has the market capitalization of $13.46 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 58.10% and monthly volatility of 23.63% respectively.
Signal Genetics, Inc. Gross Margin percentage stands at 28.6% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 159.38% with the 50-Day Simple Moving Average of 159.38 percent. Currently, the company has SMA200 (200-day simple moving average) of 134.17 Percent. The Stock has YTD (year to date) performance of 248.9 percent.
Many research firms have provided their ratings on Signal Genetics, Inc. (NASDAQ:SGNL) where Rodman & Renshaw provided Buy rating on the stock on 8-Jan-16. Other firms include Chardan Capital Markets giving Buy rating on 23-Jun-15.
The latest Insider trade was made on 30 Oct 2016 where Riccitelli (Samuel D) Chief Executive Officer did a transaction type “Buy” in which 200000 shares were traded at a price of $0. Another insider trade includes Chief Executive Officer Riccitelli (Samuel D) who also initiated a transaction in which 103160 shares were traded on 30 Oct 2016 as “Sell”.
Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York.